{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:58:18Z","timestamp":1790621898667,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821520"],"award-info":[{"award-number":["821520"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Although regulatory responses to safety signals have been studied, pregnancy\u2010specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures. A secondary aim was to investigate how information on these signals, independent of regulatory communication, was disseminated to medical professionals in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Teratological safety signals from 2002 to 2022 were retrieved from the European Pharmacovigilance Issues Tracking Tool. For each signal, we recorded the dates of market authorization, first spontaneous report, scientific publication, regulatory decision and dissemination through the Teratology Information Service (TIS) and Dutch professional journals. The source of the signal (spontaneous reports, scientific literature or otherwise) was assessed. Time intervals between events were calculated and visualized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010four safety signals pertaining to fetal teratogenesis were identified. At the time of regulatory action, medicines had been on the market for a median of 23.9\u2009years (range 3.2\u201359.3). Cases or studies published in the scientific literature were the origin for most (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918, 75%) teratological safety signals. Amendments of the product information was a regulatory action for all signals; eight (33%) also triggered Direct Healthcare Professional Communications. Apart from these regulatory communications, information may have reached healthcare professionals through scientific literature or other channels, sometimes before and sometimes alongside regulatory decisions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Teratological safety signals are predominantly scientific literature\u2010driven and often arise decades after marketing. Scientific publications and TIS may provide early guidance, frequently preceding regulatory decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70615","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:45:46Z","timestamp":1780026346000},"page":"3365-3374","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands\u2014A contribution of the ConcePTION project"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-3718","authenticated-orcid":false,"given":"Yrea R. J.","family":"van Rijt\u2010Weetink","sequence":"first","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, \u2010Epidemiology and \u2010Economics University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0764-5248","authenticated-orcid":false,"given":"Rosanne E.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, \u2010Epidemiology and \u2010Economics University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-9303","authenticated-orcid":false,"given":"Jan\u2010Peter","family":"van Wieringen","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. M. J. (Ineke)","family":"Crijns","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence P. A. M.","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, \u2010Epidemiology and \u2010Economics University of Groningen  Groningen The Netherlands"},{"name":"Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-6360","authenticated-orcid":false,"given":"Anneke L. M.","family":"Passier","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-6139","authenticated-orcid":false,"given":"Sander","family":"Borgsteede","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, \u2010Epidemiology and \u2010Economics University of Groningen  Groningen The Netherlands"},{"name":"Department of Clinical Decision Support Health Base Foundation  Houten The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-7779","authenticated-orcid":false,"given":"A. C. G. (Toine)","family":"Egberts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science Utrecht University  Utrecht The Netherlands"},{"name":"Department of Clinical Pharmacy University Medical Centre Utrecht  Utrecht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-625X","authenticated-orcid":false,"given":"Laura M.","family":"Yates","sequence":"additional","affiliation":[{"name":"University of Kwazulu\u2010Natal KRISP  Durban South Africa"},{"name":"Northern Genetics Service  Newcastle\u2010upon\u2010Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-1398","authenticated-orcid":false,"given":"Eug\u00e8ne P.","family":"van Puijenbroek","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, \u2010Epidemiology and \u2010Economics University of Groningen  Groningen The Netherlands"},{"name":"Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1728\u20104465.2014.00393.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471\u20100528.2006.00927.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1906"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11532330\u2010000000000\u201000000"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.02.029"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11589170\u2010000000000\u201000000"},{"key":"e_1_2_11_8_1","unstructured":"Guideline on the exposure to medicinal products during pregnancy: need for post \u2010 authorisation data (EMA\/CHMP\/313666\/2005).2005. Accessed June 27 2024.https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010022\u201001154\u20107"},{"key":"e_1_2_11_10_1","unstructured":"Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials. Revision 1.2018.https:\/\/www.fda.gov\/media\/112195\/download?attachment"},{"key":"e_1_2_11_11_1","unstructured":"European Medicines Agency.ICH E21 guideline on inclusion of pregnant and breastfeeding individuals in clinical trials \u2013 scientific guideline. Accessed August 15 2025 https:\/\/www.ema.europa.eu\/en\/ich-e21-guideline-inclusion-pregnant-breastfeeding-individuals-clinical-trials-scientific-guideline"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2214\u2010109x(24)00512\u20106"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17535.1"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)90927-8"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100035\u20101\u2009556\u2009743"},{"key":"e_1_2_11_16_1","unstructured":"Independent Medicines and Medical Devices Safety Review. Annex C: Sodium valproate Timeline \u2013 Key Events.2020. Accessed December 2 2025.https:\/\/www.immdsreview.org.uk\/downloads\/Annexes\/Annex-C-Valproate-timeline.pdf"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1269"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010236.pub2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2270"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469\u20108749.1994.tb11858.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25570"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12884\u2010021\u201004351\u2010x"},{"key":"e_1_2_11_23_1","unstructured":"Guideline on good pharmacovigilance practices (GVP). Module IX \u2013 Signal management (Rev 1).2017. 9 October 2017.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010018\u20100722\u20107"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1187888"},{"key":"e_1_2_11_26_1","unstructured":"Eudravigilance system overview.European Medicines Agency. Accessed July 11 2025.https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview"},{"key":"e_1_2_11_27_1","unstructured":"Website Uppsala Monitoring Centre.https:\/\/who-umc.org\/"},{"key":"e_1_2_11_28_1","unstructured":"Screening for adverse reactions in Eudravigilance.2016. EMA\/849944\/2016. Accessed December 2 2025.https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5246"},{"key":"e_1_2_11_30_1","unstructured":"Guideline on good pharmacovigilance practices (GVP) Module XVI \u2013 Risk minimisation measures (Rev 3). 26 July 2024.https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-rev-3_en.pdf"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010014\u20100240\u20101"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1526676"},{"key":"e_1_2_11_33_1","unstructured":"Medical Dictionary for Regulatory Activites. Accessed October 31 2024. www.meddra.org"},{"key":"e_1_2_11_34_1","unstructured":"Guidelines for ATC classification and DDD assignment. Accessed May 26 2026.https:\/\/atcddd.fhi.no\/atc_ddd_index_and_guidelines\/guidelines\/"},{"key":"e_1_2_11_35_1","volume-title":"European medicines agency publishes list of EU reference dates and frequency of PSUR submission"},{"key":"e_1_2_11_36_1","unstructured":"College ter Beoordeling van Geneesmiddelen.Geneesmiddeleninformatiebank (in Dutch). Accessed April 14 2025.https:\/\/www.geneesmiddeleninformatiebank.nl"},{"key":"e_1_2_11_37_1","unstructured":"PRAC recommendations on safety signalsEuropean Medicine Agency. 22 July2025 2025.https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management\/prac-recommendations-safety-signals"},{"key":"e_1_2_11_38_1","unstructured":"Heads of Medicines Agencies: Pharmacovigilance Working Party Recommendations. Accessed May 26 2026.https:\/\/www.hma.eu\/human-medicines\/cmdh\/product-information-old\/phvwp-recommendations.html"},{"key":"e_1_2_11_39_1","unstructured":"Reactions Weekly. Accessed April 28 2025.https:\/\/www.springer.com\/journal\/40278"},{"key":"e_1_2_11_40_1","unstructured":"Geneesmiddelgebruik rondom de zwangerschap (in Dutch). Accessed October 21 2025.https:\/\/www.lareb.nl\/mvm-kennis\/"},{"key":"e_1_2_11_41_1","unstructured":"Website Pharmacovigilance Centre Lareb (in Dutch). Accessed July 18 2025.http:\/\/lareb.nl\/mvm-kennis\/"},{"key":"e_1_2_11_42_1","unstructured":"Website Commentaren Medicatiebewaking (in Dutch). Accessed July 18 2025.https:\/\/www.commentarenmedicatiebewaking.nl\/"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010021\u201001308\u20100"},{"key":"e_1_2_11_44_1","unstructured":"WebsiteHealthbase. Accessed April 28 2026 2025.https:\/\/www.healthbase.nl\/"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15537"},{"key":"e_1_2_11_46_1","unstructured":"European Medicines Agency.2017.EMA seeks views of public during its safety review of valproate. Accessed August 28 2025.https:\/\/www.ema.europa.eu\/en\/news\/ema-seeks-views-public-during-its-safety-review-valproate"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3395"},{"key":"e_1_2_11_48_1","first-page":"1","volume-title":"Drugs during pregnancy","author":"K\u00e4ll\u00e9n B","year":"2009"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140\u20106736(90)91669\u20102"},{"key":"e_1_2_11_50_1","unstructured":"Guideline on good pharmacovigilance practices (GVP) Module XVI Addendum III \u2013 Pregnancy prevention programme and other pregnancy\u2010specific risk minimisation measures.2022.https:\/\/www.ema.europa.eu\/en\/dhttps:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-good-pharmacovigilance-practices-gvp-module-xvi-addendum-iii-renumbered-addendum-i-after-finalisation-pregnancy-prevention-programme-other-pregnancy-specific-risk-minimisation-measures_en.pdf"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010023\u201001314\u20103"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010023\u201001291\u20107"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70182"},{"key":"e_1_2_11_54_1","unstructured":"Guideline on good pharmacovigilance practices (GVP) Product\u2010 or Population\u2010Specific Considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk. 2 February 2026.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-iii-pregnant-breastfeeding-women-their-children-exposed-utero-or-breastmilk_en.pdf"},{"key":"e_1_2_11_55_1","unstructured":"Equity and health: the inclusion of pregnant and breastfeeding women in clinical trials.World Health Organization. Accessed April 20 2026.https:\/\/www.who.int\/news\/item\/18-06-2025-equity-and-health--the-inclusion-of-pregnant-and-breastfeeding-women-in-clinical-trials?"},{"key":"e_1_2_11_56_1","unstructured":"About OTIS the Professional Scientific Society Behind MotherToBaby. Accessed April 29 2026.https:\/\/mothertobaby.org\/about-otis\/"},{"key":"e_1_2_11_57_1","unstructured":"WebsiteEuropean Network of Teratology Information Services. Accessed April 29 2026.https:\/\/www.entis-org.eu\/"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:56:21Z","timestamp":1790618181000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70615"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70615","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}